Patterns of care in recurrent glioblastoma in Switzerland: a multicentre national approach based on diagnostic nodes

Hundsberger, T.; Hottinger, A. F.; Roelcke, U.; Roth, P.; Migliorini, D.; Dietrich, P. Y.; Conen, K.; Pesce, G.; Herrmann, Evelyn; Pica, Alessia; Gross, M. W.; Brügge, D.; Plasswilm, Ludwig; Weller, M.; Putora, P. M. (2016). Patterns of care in recurrent glioblastoma in Switzerland: a multicentre national approach based on diagnostic nodes. Journal of neuro-oncology, 126(1), pp. 175-183. Springer 10.1007/s11060-015-1957-0

Preview

Text art%3A10.1007%2Fs11060-015-1957-0.pdf - Published Version Available under License Publisher holds Copyright. Download (752kB) | Preview

Despite moderate improvements in outcome of glioblastoma after first-line treatment with chemoradiation recent clinical trials failed to improve the prognosis of recurrent glioblastoma. In the absence of a standard of care we aimed to investigate institutional treatment strategies to identify similarities and differences in the pattern of care for recurrent glioblastoma. We investigated re-treatment criteria and therapeutic pathways for recurrent glioblastoma of eight neuro-oncology centres in Switzerland having an established multidisciplinary tumour-board conference. Decision algorithms, differences and consensus were analysed using the objective consensus methodology. A total of 16 different treatment recommendations were identified based on combinations of eight different decision criteria. The set of criteria implemented as well as the set of treatments offered was different in each centre. For specific situations, up to 6 different treatment recommendations were provided by the eight centres. The only wide-range consensus identified was to offer best supportive care to unfit patients. A majority recommendation was identified for non-operable large early recurrence with unmethylated MGMT promoter status in the fit patients: here bevacizumab was offered. In fit patients with late recurrent non-operable MGMT promoter methylated glioblastoma temozolomide was recommended by most. No other majority recommendations were present. In the absence of strong evidence we identified few consensus recommendations in the treatment of recurrent glioblastoma. This contrasts the limited availability of single drugs and treatment modalities. Clinical situations of greatest heterogeneity may be suitable to be addressed in clinical trials and second opinion referrals are likely to yield diverging recommendations.

Interest & Impact

Downloads

79 since deposited on 25 Apr 2016
33 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item